Form 4 Filing for Beam Therapeutics Inc.

Christine Bellon, Chief Legal Officer of Beam Therapeutics Inc., reported a transaction on April 1, 2026, involving the sale of 5,956 shares of common stock. The sale was executed at a price of $24.58 per share, resulting in a total transaction value of $146,354.88. This transaction was a non-discretionary sale to cover tax withholding obligations upon the vesting of restricted stock units. The shares were sold under a Rule 10b5-1 trading plan adopted on May 19, 2023. Following this transaction, Bellon owns 109,711 shares of Beam Therapeutics Inc. common stock.